AT-20

AT-20 is a preclinical-stage monoclonal antibody being developed by Antharis Therapeutics for the treatment of colorectal cancer, pancreatic cancer, and gastric cancer. Antharis Therapeutics, a multinational biopharmaceutical company founded in 2020, specializes in the development of next-generation monoclonal antibodies and antibody-drug conjugates (ADCs) for oncology. The company utilizes biomarker-driven targeting and immuno-oncology approaches to enhance the immune system's ability to identify and eliminate malignant cells. As of its current stage of development, the specific molecular target and mechanism of action for AT-20 have not been publicly disclosed.